logo-loader
viewCannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics concludes successful phase 1B cannabinoid study in dogs

CannPal’s aim is to be one of the first companies to provide veterinarians with GMP-produced and regulatory approved cannabinoid-derived therapeutics for pets.

Beagle
More than 48 mixed beagles and foxhounds dosed

CannPal Animal Therapeutics Ltd (ASX:CP1) has successfully completed dosing for the phase 1B study of its lead drug candidate CPAT-01, being developed as a pain and inflammatory control for dogs.

More than 48 Beagles and Foxhounds were recruited for the study across various weights and ages.

Importantly, no adverse events were reported in dogs across all treatment groups.

READ: CannPal Animal Therapeutics caps off busy September quarter

The gene expression studies so far have revealed clear cannabinoid impact in important pain and inflammatory pathways supporting the proposed pain and inflammatory control claims for CPAT-01.

CannPal is now working with a Melbourne-based integrated medical laboratory to identify the drug’s effects on key chemokine and cytokines that are associated with the activated pain and inflammatory genes highlighted in the phase I studies.

The results of this in conjunction with the gene expression data will support the dose justification for CPAT-01 prior to commencing the clinical program.

READ: CannPal Animal Therapeutics director acquires further shares on-market

CannPal founder and managing director Layton Mills said: “I am very pleased at the speed in which we are progressing through the CPAT-01 development plan, but more importantly, the significant amounts of data we are collecting along the way.

“Our vision is to be one of the first animal health companies to provide veterinarians with GMP produced and regulatory approved cannabinoid-derived therapeutics for pets.

“We have been strict on resources and strong on creativity to ensure we remain well capitalised to continue with the development of CPAT-01 in 2019, which wouldn’t be possible without the help and support of our experienced research partners.”

Phase II study protocol development

The company has now generated significant data on the pharmacokinetic and gene expression profiles of cannabinoids in dogs.

This data will be used to commence the protocol development for the first phase II study, a pilot dose determination study in client-owned animals with osteoarthritis to clinically validate the effects seen in phase I studies.

CannPal is aiming to commence recruitment for this study in Q1 2019.

CPAT-01C cat study

The company has also received ethics approvals to commence the testing of CPAT-01 in cats.

Cats represent over 25% of the companion animal drug market and there’s a clear unmet need for safe therapeutics that can be used long-term to treat pain and inflammation in felines.

Over 20 cats have been recruited for the study across varying weights and ages.

The animal phase of the study was originally planned for Q4 2018 but is now expected to commence early in 2019 across multiple research sites.

Quick facts: CannPal Animal Therapeutics Ltd

Price: 0.125 AUD

ASX:CP1
Market: ASX
Market Cap: $11.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read